Related Experiment Video
Updated: Jun 2, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Regulation of adverse remodelling by osteopontin in a genetic heart failure model
Stelios Psarras1, Manolis Mavroidis, Despina Sanoudou
1Cell Biology Division, Center of Basic Research I, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, Athens 11527, Greece.
Aims:
Desmin, the muscle-specific intermediate filament protein, is a major target in dilated cardiomyopathy and heart failure in humans and mice. The hallmarks of desmin-deficient (des(-/-)) mice pathology include pronounced myocardial degeneration, extended fibrosis, and osteopontin (OPN) overexpression. We sought to identify the molecular and cellular events regulating adverse cardiac remodelling in des(-/-) mice and their potential link to OPN.
Methods And Results:
In situ hybridization, histology, and immunostaining demonstrated that inflammatory cells and not cardiomyocytes were the source of OPN. RNA profile comparison revealed that activation of inflammatory pathways, sustained by innate immunity mechanisms, predominated among all changes occurring in degenerating des(-/-) myocardium. The expression of the most highly up-regulated genes (OPN: 226×, galectin-3: 26×, osteoactivin/Gpnmb/DC-HIL: 160× and metalloprotease-12: 98×) was associated with heart infiltrating macrophages. To evaluate the role of OPN, we generated des(-/-)OPN(-/-) mice and compared their cardiac function and remodelling indices with those of des(-/-). Osteopontin promoted cardiac dysfunction in this model since des(-/-)OPN(-/-) mice showed 53% improvement of left ventricular function, paralleled to an up to 44% reduction in fibrosis. The diminished fibrotic response in the absence of OPN could be partly mediated by a dramatic reduction in myocardial galectin-3 levels, associated with an impaired galectin-3 secretion by OPN-deficient infiltrating macrophages.
Conclusion:
Cardiomyocyte death due to desmin deficiency leads to inflammation and subsequent overexpression of a series of remodelling modulators. Among them, OPN seems to be a major regulator of des(-/-) adverse myocardial remodelling and it functions at least by potentiating galectin-3 up-regulation and secretion.
Insights
Desmin deficiency causes heart issues, leading to inflammation and osteopontin (OPN) overexpression. Removing OPN significantly improves cardiac function and reduces fibrosis in desmin-deficient mice.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Immunology
Background:
- Desmin deficiency (des(-/-)) in mice causes myocardial degeneration, fibrosis, and osteopontin (OPN) overexpression.
- Understanding the molecular mechanisms behind cardiac remodeling in des(-/-) mice is crucial.
Purpose of the Study:
- To investigate the molecular and cellular events regulating cardiac remodeling in des(-/-) mice.
- To determine the role of osteopontin (OPN) in this process.
Main Methods:
- In situ hybridization, histology, and immunostaining to identify OPN source.
- RNA profiling to analyze gene expression changes in des(-/-) myocardium.
- Generation and comparison of des(-/-)OPN(-/-) mice with des(-/-) mice for cardiac function and remodeling.
Main Results:
- Osteopontin (OPN) is primarily overexpressed by inflammatory cells, specifically macrophages, in the degenerating des(-/-) myocardium.
- Desmin-deficient mice lacking OPN (des(-/-)OPN(-/-)) exhibited a 53% improvement in left ventricular function and up to 44% reduction in fibrosis.
- The reduced fibrosis in des(-/-)OPN(-/-) mice was associated with decreased galectin-3 levels and impaired macrophage secretion.
Conclusions:
- Cardiomyocyte death in desmin deficiency triggers inflammation and the overexpression of remodeling modulators.
- Osteopontin (OPN) significantly drives adverse cardiac remodeling in desmin deficiency.
- OPN's pro-remodeling effects involve potentiating galectin-3 upregulation and secretion.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

